Limited coverage criteria – atomoxetine

Last updated on March 17, 2025

 

Return to Special Authority drug list 

Generic name

atomoxetine

Strength & form

10 mg, 18 mg, 25 mg, 40 mg, 60 mg, 80 mg, 100 mg capsule

Special Authority criteria

Approval period

For patients 6 years of age and older diagnosed with attention deficit hyperactivity disorder (ADHD) with hyperactivity, impulsivity, or inattention that interfere with functioning

PLUS

  • Patient has been previously tried on both methylphenidate
    AND an amphetamine with unsatisfactory results or intolerance*

OR

  • Patient has contraindication(s) to stimulants

* See Special notes below

Indefinite

Practitioner exemptions

  • None

Special notes

  • Unsatisfactory trial of or intolerance to both methylphenidate AND an amphetamine: defined as no demonstrated effectiveness for symptoms of ADHD or functional impairment secondary to ADHD after a minimum 1-week trial of an adequate dose of both methylphenidate AND an amphetamine. At least one trial must be with an extended-release/long-acting stimulant. Specific details of drug, dose and duration tried, and unsatisfactory response are required, as applicable
  • Specific details of medication intolerance or contraindication must be included in the Special Authority request
  • Coverage is not intended for "performance enhancement" in patients who do not have symptoms or functional impairment
  • Criteria applicable to all plans, including Plan G

Special Authority request form(s)